Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26

Benzinga · 08/03 19:35
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.